A T-Cell Epitope-Based Multi-Epitope Vaccine Designed Using Human HLA Specific T Cell Epitopes Induces a Near-Sterile Immunity against Experimental Visceral Leishmaniasis in Hamsters
- PMID: 34696166
- PMCID: PMC8537199
- DOI: 10.3390/vaccines9101058
A T-Cell Epitope-Based Multi-Epitope Vaccine Designed Using Human HLA Specific T Cell Epitopes Induces a Near-Sterile Immunity against Experimental Visceral Leishmaniasis in Hamsters
Abstract
Visceral leishmaniasis is a neglected tropical disease affecting 12 million people annually. Even in the second decade of the 21st century, it has remained without an effective vaccine for human use. In the current study, we designed three multiepitope vaccine candidates by the selection of multiple IFN-γ inducing MHC-I and MHC-II binder T-cell specific epitopes from three previously identified antigen genes of Leishmania donovani from our lab by an immuno-informatic approach using IFNepitope, the Immune Epitope Database (IEDB) T cell epitope identification tools, NET-MHC-1, and NET MHC-2 webservers. We tested the protective potential of these three multiepitope proteins as a vaccine in a hamster model of visceral leishmaniasis. The immunization data revealed that the vaccine candidates induced a very high level of Th1 biased protective immune response in-vivo in a hamster model of experimental visceral leishmaniasis, with one of the candidates inducing a near-sterile immunity. The vaccinated animals displayed highly activated monocyte macrophages with the capability of clearing intracellular parasites due to increased respiratory burst. Additionally, these proteins induced activation of polyfunctional T cells secreting INF-γ, TNF-α, and IL-2 in an ex-vivo stimulation of human peripheral blood mononuclear cells, further supporting the protective nature of the designed candidates.
Keywords: IFN-γ epitope; Leishmania; T cell; epitopes; hamster; sterile immunity; vaccine.
Conflict of interest statement
The authors declare no conflict of interest.
Figures






Similar articles
-
Design of multi-epitope peptides containing HLA class-I and class-II-restricted epitopes derived from immunogenic Leishmania proteins, and evaluation of CD4+ and CD8+ T cell responses induced in cured cutaneous leishmaniasis subjects.PLoS Negl Trop Dis. 2020 Mar 16;14(3):e0008093. doi: 10.1371/journal.pntd.0008093. eCollection 2020 Mar. PLoS Negl Trop Dis. 2020. PMID: 32176691 Free PMC article.
-
Genome based screening of epitope ensemble vaccine candidates against dreadful visceral leishmaniasis using immunoinformatics approach.Microb Pathog. 2019 Nov;136:103704. doi: 10.1016/j.micpath.2019.103704. Epub 2019 Aug 31. Microb Pathog. 2019. PMID: 31479726
-
Immuno-informatics based approaches to identify CD8+ T cell epitopes within the Leishmania donovani 3-ectonucleotidase in cured visceral leishmaniasis subjects.Microbes Infect. 2017 Jun;19(6):358-369. doi: 10.1016/j.micinf.2017.03.002. Epub 2017 Apr 1. Microbes Infect. 2017. PMID: 28373107
-
Identification of Potential MHC Class-II-Restricted Epitopes Derived from Leishmania donovani Antigens by Reverse Vaccinology and Evaluation of Their CD4+ T-Cell Responsiveness against Visceral Leishmaniasis.Front Immunol. 2017 Dec 14;8:1763. doi: 10.3389/fimmu.2017.01763. eCollection 2017. Front Immunol. 2017. PMID: 29312304 Free PMC article.
-
Role of pro-inflammatory cytokine IL-17 in Leishmania pathogenesis and in protective immunity by Leishmania vaccines.Cell Immunol. 2016 Nov;309:37-41. doi: 10.1016/j.cellimm.2016.07.004. Epub 2016 Jul 11. Cell Immunol. 2016. PMID: 27444130 Review.
Cited by
-
In silico designed Staphylococcus aureus B-cell multi-epitope vaccine did not elicit antibodies against target antigens suggesting multi-domain approach.J Immunol Methods. 2022 May;504:113264. doi: 10.1016/j.jim.2022.113264. Epub 2022 Mar 25. J Immunol Methods. 2022. PMID: 35341759 Free PMC article.
-
An immunoinformatics approach for a potential NY-ESO-1 and WT1 based multi-epitope vaccine designing against triple-negative breast cancer.Heliyon. 2024 Aug 28;10(17):e36935. doi: 10.1016/j.heliyon.2024.e36935. eCollection 2024 Sep 15. Heliyon. 2024. PMID: 39286192 Free PMC article.
-
Synthetic biology for combating leishmaniasis.Front Microbiol. 2024 Feb 1;15:1338749. doi: 10.3389/fmicb.2024.1338749. eCollection 2024. Front Microbiol. 2024. PMID: 38362504 Free PMC article.
-
Design and development of highly conserved, HLA-promiscuous T cell multiepitope vaccines against human visceral leishmaniasis.Front Immunol. 2025 Mar 31;16:1540537. doi: 10.3389/fimmu.2025.1540537. eCollection 2025. Front Immunol. 2025. PMID: 40230841 Free PMC article.
-
Efficacy of vaccines based on chimeric or multiepitope antigens for protection against visceral leishmaniasis: A systematic review.PLoS Negl Trop Dis. 2024 Dec 31;18(12):e0012757. doi: 10.1371/journal.pntd.0012757. eCollection 2024 Dec. PLoS Negl Trop Dis. 2024. PMID: 39739955 Free PMC article.
References
-
- WHO|Weekly Epidemiological Record. [(accessed on 19 November 2020)];2017 September 22;Volume 92:557–572. Available online: http://www.who.int/wer/2017/wer9238/en/
-
- Medina-Colorado A.A., Osorio E.Y., Saldarriaga O.A., Travi B.L., Kong F., Spratt H., Soong L., Melby P.C. Splenic CD4+ T Cells in Progressive Visceral Leishmaniasis Show a Mixed Effector-Regulatory Phenotype and Impair Macrophage Effector Function through Inhibitory Receptor Expression. PLoS ONE. 2017;12:e0169496. doi: 10.1371/journal.pone.0169496. - DOI - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous